A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system DOI Creative Commons
Jingjing Huang,

Xiaohong Long,

Chunyong Chen

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: March 13, 2025

Background Alzheimer’s disease poses a major public health challenge, with aducanumab’s approval in 2021 as the first disease-modifying therapy raising important safety considerations. This study analyzed Food Drug Administration Adverse Event Reporting System (FAERS) database to evaluate real-world profile and identify potential risk factors. Methods We conducted comprehensive pharmacovigilance using FAERS from January 2004 June 2024, analyzing 510 aducanumab-associated reports integrated databases containing over 18 million demographic records 66 drug records. Safety signals were evaluated four complementary disproportionality methods: Odds Ratio (ROR), Proportional (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), Multi-item Gamma Poisson Shrinker (MGPS). Analyses stratified by age sex, adverse events examined at both Organ Class (SOC) Preferred Term (PT) levels SAS 9.4. Results Among event reports, predominantly elderly patients (55.49% aged ≥65 years), nervous system disorders most frequent (53.24%, n = 583). Amyloid related imaging abnormality-oedema/effusion (ARIA-E) abnormality-microhaemorrhages haemosiderin deposits (ARIA-H) emerged significant (ROR: 53,538.3 38,187.9, respectively). Sex-stratified analysis showed comparable profiles between males females, ARIA-E events, ARIA-H maintaining strong across all groups, particularly ≥75 years. The median time onset was 146.0 days (IQR: 80.0–195.0). Temporal revealed increasing signal strength for ARIA-related 2004–2024, notable intensification during 2022–2023. Conclusion Our identified primary concern aducanumab, typically occurring within 146 of treatment initiation, sex but heightened risks These findings support viability therapeutic option while emphasizing critical importance rigorous monitoring protocols, ARIA year treatment.

Language: Английский

Biological and Physical Performance Markers for Early Detection of Cognitive Impairment in Older Adults DOI Open Access
Hanna Kerminen, Emanuele Marzetti, Emanuela D’Angelo

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(3), P. 806 - 806

Published: Jan. 30, 2024

Dementia is a major cause of poor quality life, disability, and mortality in old age. According to the geroscience paradigm, mechanisms that drive aging process are also involved pathogenesis chronic degenerative diseases, including dementia. The dissection such therefore instrumental providing biological targets for interventions new sources biomarkers. Within several biomarkers have been discovered can be measured blood allow early identification individuals at risk cognitive impairment. Examples markers include inflammatory biomolecules, neuroaxonal damage, extracellular vesicles, DNA methylation. Furthermore, gait speed, usual fast pace as part dual task, has shown detect future Here, we provide an overview available may used gauge impairment apparently healthy older adults. Further research should establish which combination possesses highest predictive accuracy toward incident implementation currently large share at-risk whom preventive implemented maintain or increase reserves, thereby reducing progression

Language: Английский

Citations

5
Emerging role of Metformin in Alzheimer’s disease: A translational view DOI

Juvenal A. Ríos,

Juan Carlos Bórquez, Juan A. Godoy

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 100, P. 102439 - 102439

Published: July 27, 2024

Language: Английский

Citations

5
Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer’s Disease, a Potential Therapeutic Target DOI Creative Commons
Nidhi Puranik, Minseok Song

Molecules, Journal Year: 2024, Volume and Issue: 29(23), P. 5744 - 5744

Published: Dec. 5, 2024

Gamma-glutamate is an important excitatory neurotransmitter in the central nervous system (CNS), which plays role transmitting synapses, plasticity, and other brain activities. Nevertheless, alterations glutamatergic signaling pathway are now accepted as a element Alzheimer's disease (AD) pathophysiology. One of most prevalent types dementia older adults AD, progressive neurodegenerative illness brought on by persistent decline cognitive function. Since AD has been shown to be multifactorial, variety pharmaceutical targets may used treat condition. N-methyl-D-aspartic acid receptor (NMDAR) antagonists acetylcholinesterase inhibitors (AChEIs) two drug classes that Food Drug Administration authorized for treatment AD. The AChEIs approved galantamine, donepezil, rivastigmine. However, memantine only non-competitive NMDAR antagonist This review aims outline involvement glutamate (GLU) at molecular level pathways associated with demonstrate target therapeutic potential its receptor. We will also consider opinion leading authorities working this area, drawback existing strategies, direction further investigation.

Language: Английский

Citations

5
Unveiling the role of astrogliosis in Alzheimer’s disease Pathology: Insights into mechanisms and therapeutic approaches DOI

Mohit Paidlewar,

Sneha Kumari,

Rishika Dhapola

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 112940 - 112940

Published: Aug. 17, 2024

Language: Английский

Citations

4
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease DOI
Akanksha Chhabra, Siddhant Solanki,

Prithvi Saravanabawan

et al.

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(11), P. 1261 - 1269

Published: Oct. 21, 2024

Introduction Alzheimer's disease can cause dementia through brain matter degradation. This study investigates the monoclonal antibody usage for AD treatment, following PRISMA 2020 guidelines, and aims to discern that offers optimal balance of efficacy safety individuals with AD.

Language: Английский

Citations

4
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease DOI Creative Commons
Andrew J. Petkus, Anup N. Sonti,

Lucy Montoya

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: 12(1), P. 100010 - 100010

Published: Jan. 1, 2025

Declining motor abilities might be a noninvasive biomarker for Alzheimer's disease (AD). Studying ability and AD progression in younger Latinos with autosomal dominant (ADAD) can provide insights into the interplay between cognition individuals minimal confounding from age-normative changes comorbid medical conditions. This study aimed to (1) examine as function of years dementia diagnosis (2) associations cognitive performance. was cross-sectional observational study. The took place at University Southern California. 39 predominately Latino (mean age 38.6 ± 10 old) known carry (carriers; n=25) or 50% risk inheriting ADAD but not carrying mutation (noncarriers; n=14). Individuals completed batteries National Institute Health Toolbox (NIHTB) Cognitive Abilities Screening Instrument (CASI). All models included effects age, education, primary language, sex. Compared noncarriers, carriers had significantly weaker grip strength 12 years, worse manual dexterity slower gait speed seven before expected diagnosis. Worse associated more severe stage CASI performance, adjusting demographic clinical variables. findings support utility precisely strength, dexterity, potential biomarkers preclinical AD.

Language: Английский

Citations

0
The Research Progress of Drugs for Treatment of AlzheimerS Disease DOI Creative Commons
Yuchen Zhang

Theoretical and Natural Science, Journal Year: 2025, Volume and Issue: 68(1), P. 221 - 226

Published: Jan. 13, 2025

In this society, Alzheimer's disease represents a significant public health concern. Nevertheless, the market offers only two FDA-approved drugs, which are capable of partially inhibiting symptoms. It is imperative that both patients and researchers made aware mechanism by AD triggered fundamental logic underlying action each drug. This should include an understanding how drug reacts with body ingredients it contains. section primarily discusses therapeutic options for disease, encompassing drugs mechanisms currently available on those have not yet been approved but theoretically feasible. passage will introduce number potential treatments including Chinese patent medicine, acetylcholinesterase inhibitors, NMDA receptor antagonists, Aduhelm, Leqembi, anti-amyloid therapies A immunotherapies. Despite existence these many years, still possible to cure completely or delay prevent its progression. aims provide insights into future direction pharmaceutical research selection appropriate medications

Language: Английский

Citations

0
Dysregulation of the molecular clock by blood-borne factors in Alzheimer’s disease patients DOI

Chunsong Zhao,

Taoran Li, Shuwen Hao

et al.

Journal of Neurology, Journal Year: 2025, Volume and Issue: 272(2)

Published: Jan. 15, 2025

Language: Английский

Citations

0
Sequence of decline on the NIH-toolbox cognitive battery in a predominantly Latino sample with autosomal dominant Alzheimer's disease DOI Creative Commons
Andrew J. Petkus, Anup N. Sonti,

Lucy Montoya

et al.

Journal of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 26, 2025

Understanding the sequential progression of cognitive decline in autosomal dominant Alzheimer's disease (ADAD) Latino population is crucial for enhancing early identification targeted interventions. Given tablet-based administration and increasing frequency use epidemiological research, validating this within NIH Toolbox battery (NIHTB-CB) important. The first aim was to utilize an innovative Event-Based Modeling (EBM) analytic approach estimate sequence declines persons at risk ADAD enriched being origin. second examine associations between EBM-derived estimates severity independent outcomes carriers noncarriers. This cross-sectional observational study (N = 30) included 16 mutation 14 noncarriers who completed NIHTB-CB their primary language (n 8 Spanish; n 22 English). An EBM constructed compare on performance. We utilized linear regression cognitive-decline stage (e.g., performance Cognitive Abilities Screening Instrument (CASI) estimated years dementia diagnosis). that tests assessing episodic memory were become abnormal ADAD-related decline. Each higher associated with approximately a three-point CASI two closer diagnosis. Findings support applied likely Latinos ADAD.

Language: Английский

Citations

0
Mitochondrial Alterations, Oxidative Stress, and Therapeutic Implications in Alzheimer’s Disease: A Narrative Review DOI Creative Commons

Erica Spina,

Riccardo Rocco Ferrari, Elisa Pellegrini

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(3), P. 229 - 229

Published: Feb. 6, 2025

The relationship between aging, mitochondrial dysfunction, neurodegeneration, and the onset of Alzheimer’s disease (AD) is a complex area study. Aging primary risk factor for AD, it associated with decline in function. This dysfunction believed to contribute neurodegenerative processes observed AD. Neurodegeneration AD characterized by progressive loss synapses neurons, particularly regions brain involved memory cognition. It hypothesized that plays pivotal role disrupting cellular energy metabolism increasing production reactive oxygen species (ROS), which can damage components exacerbate neuronal loss. Despite extensive research, precise molecular pathways linking pathology are not fully understood. Various hypotheses have been proposed, including cascade hypothesis, suggests an early event pathogenesis triggers events leading neurodegeneration. With this narrative review, we aim summarize some specific issues literature on mitochondria their involvement onset, focus development therapeutical strategies targeting environment potential application treatment itself.

Language: Английский

Citations

0